Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments

Journal of Biopharmaceutical Statistics

Volumn 18, Issue 2, 2008, Pages 342-358

  Ogungbenro, Kayode ^a   Graham, Gordon ^b   Gueorguieva, Ivelina ^c   Aarons, Leon ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

D optimality; Fisher information matrix; Multiresponse; Optimal design; Pharmacodynamics; Population pharmacokinetics

Indexed keywords

9 AMINOCAMPTOTHECIN; RUBITECAN;

ACCURACY; ARTICLE; CORRELATION ANALYSIS; COVARIANCE; EXPERIMENTAL DESIGN; FISHER EXACT TEST; INDIVIDUAL BASED POPULATION MODEL; INTERMETHOD COMPARISON; PHARMACOKINETICS; POPULATION RESEARCH; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS; VARIANCE;

DRUG DESIGN; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; RESEARCH DESIGN;

EID: 40449086351     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400701697208     Document Type: Article

References (24)

1. al Banna, M. K., Kelman, A. W., Whiting, B. (1990). Experimental design and efficient parameter estimation in population pharmacokinetics. J. Pharmacokinet. Biopharm. 18:347-360.
2. Box, M. J., Draper, N. R. (1970). Estimation and design for multiresponse nonlinear models, nonhomogenous variance structure. Annals of Mathematical Statistics 41:1391.
3. Draper, N. R., Hunter, W. G. (1966). Design of experiments for parameter estimation in multiresponse situations. Biometrika 53:525-533.
4. Duffull, S. (2006). POPT, Optimization for population PKPD study design. http://www.uq.edu.au/pharmacy/sduffull/POPT.htm.
5. Duffull, S. B., Retout, S., Mentré, F. (2002). The use of simulated annealing for finding optimal population designs. Comput. Methods Programs Biomed. 69:25-35.
6. Fedorov, V. V. (1972). Theory of Optimal Experiments. New York: Academic Press.
7. Foracchia, M., Hooker, A., Vicini, P., Ruggeri, A. (2004). POPED, a software for optimal experiment design in population kinetics. Comput. Methods Programs Biomed. 74:29-46.
8. Gagnon, R., Leonov, S. (2005). Optimal population designs for PK models with serial sampling. J. Biopharm. Stat. 15:143-163.
9. Graham, G., Aarons, L. (2006). Optimal blood sampling time windows for parameter estimation in individual and population pharmacokinetic experiments. Stat. Med. 25:4004-4019.
10. Gueorgueiva, I., Aarons, L., Ogungbenro, K., Jorga, K. M., Rodgers, T., Rowland, M. (2006). Optimal design for multivariate response pharmacokinetic models. J. Pharmacokinet. Pharmacodyn. 33:97-124.
11. Gueorgueiva, I., Ogungbenro, K., Graham, G., Glatt, S., Aarons, L. (2007). A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models. Comput. Methods Programs Biomed. Accepted.
12. Holford, N. H. G., Gobburu, J. V. S., Mould, D. R. (2003). Implications of including and excluding correlation of random effects in hierarchical mixed effects pharmacokinetic models. PAGE 12: abstract 374. http://www.pagemeeting.org/default.asp?abstract=374.
13. Hooker, A., Vicini, P. (2005). Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments. AAPS Journal 7:E759-E785.
14. Mandema, J. W., Verotta, D., Sheiner, L. B. (1992). Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokinet. Biopharm. 20:511-528.
15. Mentré, F., Mallet, A., Baccar, D. (1997). Optimal design in random-effects regression models. Biometrika 84:429-442.
16. Ogungbenro, K., Graham, G., Gueorgueiva, I., Aarons, L. (2005). The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments. Comput. Methods Programs Biomed. 80:115-125.
17. Ogungbenro, K., Gueorgueiva, I., Majid, O., Graham, G., Aarons, L. (2007). Optimal design for multiresponse pharmacokinetic-pharmacodynamic models: Dealing with unbalanced designs. J. Pharmacokinet. Pharmacodyn. 34:313-331.
18. Retout, S., Duffull, S., Mentré, F. (2001). Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput. Methods Programs Biomed. 65:141-151.
19. Retout, S., Mentré, F. (2003a). Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. J. Biopharm. Stat. 13:209-227.
20. Retout, S., Mentré, F. (2003b). Optimization of individual and population designs using Splus. J. Pharmacokinet. Pharmacodyn. 30:417-443.
21. Retout, S., Mentré, F. (2005). Population design optimisation: PFIMOPT 1.0. http://www.bichat.inserm.fr/equipes/Emi0357/download.html.
22. Retout, S., Mentré, F., Bruno, R. (2002). Fisher information matrix for non-linear mixed-effects models: Evaluation and application for optimal design of enoxaparin population pharmacokinetics. Stat. Med. 21:2623-2639.
23. Schoemaker, N. E., Mathot, R. A., Schoffski, P., Rosing, H., Schellens, J. H., Beijnen, J. H. (2002). Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule. Cancer Chemother. Pharmacol. 50:514-517.
24. Waterhouse, T. H., Redmann, S., Duffull, S. B., Eccleston, J. A. (2005). Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. J. Pharmacokinet. Pharmacodyn. 32:521-545.